Dianthus Therapeutics, INC /DE/ Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Fairmount Funds Management LLC and its affiliates have reduced their beneficial ownership in Dianthus Therapeutics, Inc. to below 5%, marking an exit filing.
NASDAQ
Avidity Partners Management LP and its affiliates have reduced their beneficial ownership in Dianthus Therapeutics, Inc. to below 5%, filing an exit amendment to their Schedule 13D.
NASDAQ
Fairmount Funds Management and its affiliates increased their beneficial ownership in Dianthus Therapeutics to 9.9% following a $19.8 million share purchase.
NASDAQ
SCHEDULE 13D/A: Avidity Partners Reduces Stake in Dianthus Therapeutics to 9.9% Following Significant Share Sale
Avidity Partners Management LP and its affiliates have filed an Amendment No. 2 to Schedule 13D, reporting a decrease in their beneficial ownership of Dianthus Therapeutics, Inc. common stock to 9.9% following a significant share sale.